1. Home
  2. SAFE vs WVE Comparison

SAFE vs WVE Comparison

Compare SAFE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$13.51

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

HOLD

Current Price

$4.24

Market Cap

957.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
WVE
Founded
2016
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
957.7M
IPO Year
1999
2015

Fundamental Metrics

Financial Performance
Metric
SAFE
WVE
Price
$13.51
$4.24
Analyst Decision
Hold
Strong Buy
Analyst Count
10
16
Target Price
$19.00
$29.81
AVG Volume (30 Days)
312.0K
2.9M
Earning Date
04-30-2026
04-28-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.82
N/A
Revenue
$385,552,000.00
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
$85.67
P/E Ratio
$16.04
N/A
Revenue Growth
5.43
149.43
52 Week Low
$12.76
$4.31
52 Week High
$17.45
$21.73

Technical Indicators

Market Signals
Indicator
SAFE
WVE
Relative Strength Index (RSI) 28.66 28.19
Support Level $13.36 N/A
Resistance Level $15.59 $6.33
Average True Range (ATR) 0.42 0.21
MACD -0.12 -0.03
Stochastic Oscillator 17.81 3.38

Price Performance

Historical Comparison
SAFE
WVE

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: